1stOncology™: Cancer Intelligence Service – Page 5 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

BullFrog AI to Participate in the BTIG Virtual Biotechnology Conference

On July 22, 2026 BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), an AI company using three complementary capabilities to turn complex biomedical data into actionable insights, reported that the Company’s management team will participate in the BTIG Virtual Biotechnology Conference being held on July 28-29, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

BTIG’s virtual event will host established and emerging healthcare company management teams for one-on-one investor meetings and thematic panel discussions with industry leaders.

Management will be participating in one-on-one investor meetings on Wednesday, July 29th. Investors interested in scheduling a meeting with the BullFrog AI management team should contact their BTIG representative.

(Press release, Bullfrog AI, JUL 22, 2026, View Source [SID1234669363])

Nykode Therapeutics Presents Comprehensive Preclinical Data, Optimized Manufacturing, and Durable Clinical Immunogenicity for their Individualized Neoantigen Therapy VB10.NEO

On July 22, 2026 Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, reported comprehensive preclinical and clinical data on VB10.NEO, its individualized neoantigen therapy (INT), at the Neoantigen Summit in Amsterdam, reinforcing the program as a differentiated platform ready for strategic partnership.

VB10.NEO is a wholly owned, DNA-based INT built on Nykode’s proprietary antigen presenting cell (APC)-targeting technology and NeoSELECTTM, an AI-driven neoantigen selection engine.

The preclinical data demonstrates the strength of Nykode’s differentiated APC-targeting, DNA-based vaccine platform, which shows a strong immunogenicity advantage over non-APC-targeted vaccines. New data showcases further enhanced immune responses with co-administration of molecular adjuvants. VB10.NEO generated robust CD4+ and CD8+ T cell responses across multiple tumor models, demonstrated stronger immune responses than peptide vaccines, durable tumor protection, and improved anti-tumor activity in combination with anti-CTLA4 or anti-PD-L1 antibody checkpoint inhibitors.

Nykode is dedicated to leverage AI and machine learning to optimize vaccine design, with new data demonstrating improved antigen secretion and selection of complex antigen designs.

"VB10.NEO is a highly differentiated individualized neoantigen therapy, combining broad, durable immune responses with scalable manufacturing. Together with our new data pointing to further optimized immune responses and further reduced manufacturing timelines, we have strengthened our confidence around VB10.NEO’s potential." said Agnete Fredriksen, CSO and Co-founder of Nykode Therapeutics.

Nykode has established a clinically validated end-to-end manufacturing process for VB10.NEO, achieving 100% manufacturing success across two clinical trials. Recent improvements have meaningfully reduced manufacturing time, with a current process of under six weeks from biopsy to release. This positions Nykode as one of the fastest and most robust INT developers on the market. Future establishment of an in-house process will create a scalable, time- and cost-competitive supply chain where Nykode’s simpler plasmid DNA manufacturing process will have an inherent cost-of-goods and needle to needle time advantage over alternative technologies such as mRNA-LNP.

NeoSELECTTM, Nykode’s proprietary AI-powered neoantigen selection algorithm, demonstrated a significant correlation between highly ranked neoantigens and immunogenicity in patients. The platform was recently strengthened by a new U.S. patent extending protection through 2039.

Across two clinical trials in advanced solid tumors, VB10.NEO was safe and well tolerated, with no serious vaccine-related adverse events. Vaccine-specific immune responses were observed in 88-100% of patients, including de novo T cell responses in 85% of patients, and remained durable for more than one year after the final dose.

A new post-hoc analysis indicates that patients with a higher number of vaccine-induced immune responses showed a trend toward improved overall survival, while patients with baseline immune response to a higher number of the selected neoantigens had a significant correlation with improved overall survival, indicating that Nykode’s vaccines target clinically meaningful neoantigens. Importantly, in patients with baseline immune response to a lower number of neoantigens, a higher number of de novo vaccine-induced immune responses was significantly correlated with an overall survival benefit, indicating the potential of VB10.NEO to target relevant neoantigens and provide clinical benefit to cancer patients with an insufficient immune response to these neoantigens.

Nykode is actively exploring partnerships to advance VB10.NEO across a broad range of tumor types.

The poster will be available after the session at the Company’s Webpage:
View Source

(Press release, Nykode Therapeutics, JUL 22, 2026, View Source [SID1234669362])

Vaxart to Participate in BTIG Biotechnology Conference 2026

On July 21, 2026 Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, reported that members of its management team will participate in the BTIG Virtual Biotechnology Conference taking place virtually July 28, 2026.

BTIG Biotechnology Conference 2026
Date: Tuesday, July 28, 2026
Format: 1×1 Meetings
Location: Virtual

Institutional Investors interested in meeting with Vaxart management should contact their BTIG representative.

(Press release, Vaxart, JUL 21, 2026, View Source [SID1234669361])

TLX591-Tx ProstACT SELECT Study Published in Cancers Journal

On July 21, 2026 Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") reported publication of results from the ProstACT SELECT study in Cancers, a peer-reviewed journal. The Phase 1 study evaluated TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan), Telix’s first-in-class prostate-specific membrane antigen (PSMA) targeting radio antibody-drug conjugate (rADC) therapy candidate. The study’s scientific purpose was to evaluate lesion concordance between 68Ga-PSMA-PET5 and multi-time point SPECT6 imaging for patient selection using a "theranostic" approach.

The publication highlights TLX591-Tx’s differentiated clinical profile, including an intensified dosing schedule, prolonged tumor retention and low exocrine (salivary) gland irradiation. The authors also concluded that in a heterogeneous population representative of a real-world setting, TLX591-Tx therapy in combination with standard of care (SOC) demonstrated a manageable and predictable safety profile, and indicative efficacy with a median radiographic progression-free survival (rPFS) of 8.8 months reported in evaluable patients.

Nat Lenzo, MD, Nuclear Medicine Oncologist and Principal Investigator on the ProstACT SELECT study commented, "A key objective of ProstACT SELECT was to determine whether PSMA-PET imaging could reliably identify patients suitable for TLX591-Tx therapy, and the results clearly support this approach. The results provide compelling evidence that the PSMA-PET imaging agent and TLX591-Tx are targeting the same disease sites, supporting the ongoing ProstACT Global trial for mCRPC7, where there remains significant unmet need for additional treatment options."

David N. Cade, MD, Group Chief Medical Officer, Telix, said, "The publication of ProstACT SELECT data further strengthens the scientific foundation for Telix’s lead therapeutic candidate, TLX591-Tx. The peer-reviewed results support our patient-selection strategy and demonstrate a differentiated pharmacologic profile characterized by durable tumor targeting, hepatobiliary clearance, and a manageable safety profile. Telix is further evaluating TLX591-Tx in the international multi-center Phase 3 ProstACT Global study, where we aim to meaningfully improve outcomes for patients living with advanced prostate cancer."

The full paper is available at: View Source

About ProstACT SELECT

The purpose of the ProstACT SELECT trial was to evaluate the utility of 68Ga-PSMA-PET imaging (Illuccix) to select patients for TLX591-Tx rADC therapy. The primary objectives were to determine whole body biodistribution and organ radiation dosimetry and assess the safety and tolerability of TLX591-Tx in patients with advanced mCRPC. rPFS was a secondary study objective.

(Press release, Telix Pharmaceuticals, JUL 21, 2026, View Source [SID1234669360])

Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference

On July 21, 2026 Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, reported that the company will deliver an oral presentation and present a poster at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Drug Discovery and Development, or AACR (Free AACR Whitepaper) D3, Conference, taking place July 21–24, 2026 in Boston.

The presentations will highlight the broad and actionable capabilities of the AP3 platform to rapidly identify and advance promising compounds into clinical development, focusing on the discovery of ACR-2316, the company’s novel clinical-stage, selective WEE1/PKMYT1 inhibitor.

Data being presented illustrate how AP3 can uncover drug-induced resistance mechanisms, in this case WEE1 inhibition-induced activation of PKMYT1, resulting in phosphorylation of CDK1 on Thr14, a direct PKMYT1 phosphorylation site. Moreover, AP3 enabled the development of ACR-2316 based on optimal intracellular pathway effects, including sustained activation of CDK1, CDK2, but importantly and also of PLK1, to drive potent pro-apoptotic tumor cell death.

"We are excited to present at AACR (Free AACR Whitepaper) D3 and to highlight the actionable power of our AP3 platform to rapidly translate intracellular pathway biology into differentiated drug candidates," said Kristina Masson, Ph.D., co-founder and EVP at Acrivon, and president and CEO of the company’s research subsidiary, Acrivon AB, in Lund, Sweden. "Our presentations underscore how AP3 moves beyond traditional target-centric drug discovery by directly measuring drug-regulated pathway activity in intact cells, enabling optimal biology-based design of compounds for superior clinical activity and patient benefit. ACR-2316 is a compelling example of this strategy, and we look forward to sharing our findings at the conference."

ACR-2316 is currently in a Phase 1/2 clinical study advancing toward the dose expansion phase. Initial observations have shown tumor shrinkage, including PRs, and durable clinical benefit in subjects with small cell lung cancer (SCLC), squamous non-small cell lung cancer (sqNSCLC), and adenosarcoma NSCLC (adNSCLC), AP3-predicted tumor types not previously shown to be sensitive to other clinical WEE1 or PKMYT1 inhibitors. The compound has also demonstrated a favorable, differentiated tolerability profile observed in studies conducted to date, with adverse events primarily limited to only transient, mechanism-based neutropenia and a notable absence of non-hematological adverse events.

Presentations and Details

Oral Podium Presentation

Title: Acrivon Predictive Precision Proteomics (AP3): Next Generation Precision Medicine for Phosphoproteomics-Guided Drug Discovery
Presenter: Lei Shi, Ph.D., Director and Head, AP3 Pathway Discovery, Acrivon Therapeutics
Session: Biotech Spotlight Session 1: Novel Therapeutics
Date and Time: Thursday, July 23, 2026, 3:50–4:00 p.m. ET
Location: Grand Ballroom

Poster Presentation

Title: AP3-guided biological SAR enables discovery of ACR-2316, a novel clinical-stage WEE1/PKMYT1 inhibitor designed for CDK1/2 and PLK1 pathway activation
Poster Number: A082
Session: Poster Session A
Date and Time: Wednesday, July 22, 2026, 6:15–8:45 p.m. ET
Location: Back Bay Ballroom

(Press release, Acrivon Therapeutics, JUL 21, 2026, View Source [SID1234669359])